<DOC>
	<DOCNO>NCT02686203</DOCNO>
	<brief_summary>evaluate The Investigational Therapy effect quality life , pain patient 's clinical status adult cancer patient solid tumor longer candidate active oncological therapy .</brief_summary>
	<brief_title>Evaluate Effectiveness Low Level Laser Therapy ( LLT ) Combined With Acupuncture</brief_title>
	<detailed_description>evaluate The Investigational Therapy effect quality life , pain patient 's clinical status adult cancer patient solid tumor longer candidate active oncological therapy . Eligible patient enrol study receive least two 20-min treatment session , 2 12 week apart , Investigational Therapy healthy body tissue ( i.e . non-tumor region ) back hand and/or foot . Number treatment session treatment frequency individualize per patient depend patient 's status well per discretion treat therapist , specialize experienced use Investigational Therapy . Patients assessed quality life , pain patient 's clinical status accord acceptable clinical evaluation . If time start study , decide initiate active oncological treatment , principal investigator designee inform Sponsor . The Sponsor decide patient stay discontinue study .</detailed_description>
	<criteria>1 . Male female patient 18 70 year age diagnose cancer ( without metastasis ) include limited breast , ovarian , cervical , uterine , renal , bladder , gastric , pancreas , lung , thyroid , colorectal , small large intestine , testicle prostate cancer either 1. failed standard treatment type cancer 2. decline standard treatment interested noninvasive treatment change life style 3. time decide treatment option interested noninvasive treatment 2 . Confirm cancer diagnosis use biopsy , biomarkers image ( PET/CT , MRI , CT , Ultrasound , etc . ) 3 . Karnofsky performance status score least 60 % lung cancer least 50 % cancer screen visit 4 . Life expectancy least 12 week 5 . Patients must adequate organ function define : 1 . AST ( SGOT ) /ALT ( SGPT ) &lt; 3x upper limit normal ( ULN ) . 2 . Serum creatinine &lt; 2.0 mg/dL . 3 . Serum bilirubin &lt; 3 mg/dL 6 . Signed write informed consent participate study independently patient . 7 . Ability comply requirement study . 1 . Participation interventional investigational trial within 30 day screen visit . 2 . Receipt chemotherapy radiotherapy within 1 month screen visit 3 . Patients concurrent severe and/or uncontrolled medical condition could compromise participation study interfere evaluation investigational therapy effect ( i.e . active infection , uncontrolled diabetes , uncontrolled hypertension , congestive cardiac failure , unstable angina , ventricular arrhythmia , active ischemic heart disease , myocardial infarction within six month , chronic liver renal disease , active upper gastrointestinal tract ulceration ) . 4 . Any form substance abuse ( include drug alcohol abuse ) , psychiatric disorder chronic condition susceptible , opinion investigator sponsor , interfere conduct study . 5. likely noncompliant uncooperative study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>